Long-term Stability of Peri-implantitis Treatments: a 3-year Clinical Evaluation

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorRamón Pons Calabuig

About this trial

This prospective study will include patients previously enrolled in the PER-ECL-2019-05 trial who attend the Department of Periodontology (CUO) for maintenance therapy or treatment of periodontal and/or peri-implant diseases, provided they meet the inclusion criteria.

Initially, 36 patients with advanced peri-implantitis were enrolled in a randomized clinical trial evaluating the clinical, radiographic and patient-related outcomes of reconstructive therapy following a non-surgical phase of peri-implantitis treatment compared to non-surgical treatment alone (PER-ECL-2019-05) (10).

At the study conclusion 34 patients were re-evaluated and 2 patients were excluded from the study (10).

In the original study, adult patients presenting at least one titanium implant diagnosed with peri-implantitis were identified among patients referred to the Department of Periodontology of UIC between January 2020 and October 2022. Peri-implantitis was diagnosed following the case definition of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions (11) that is, PPD ≥ 6 mm combined with bleeding on probing (BOP) and/or suppuration (SUP), together with progressive bone loss in relation to the radiographic bone level assessment. In those cases where initial radiograph was unavailable, the definition of a peri-implantitis case was based on radiographic evidence of bone level ≥3 mm apical to the most coronal portion of the intra-osseous part of the implant (12).

At the outset of the original study, participants were randomly assigned to one of two groups:

The first group received only non-surgical therapy for peri-implantitis, while the second group underwent a non-surgical phase followed by reconstructive surgical treatment. This design allowed for direct comparison of the clinical, radiographic, and patient-centered outcomes between the two treatment modalities. Both groups were managed and evaluated according to standardized protocols, ensuring consistency and reliability of the results at 12 months .

Patients who have not returned to the Department will be contacted by telephone and invited to participate through the academic office.

At 36 months, a single follow-up will be carried out including:

A detailed clinical examination. A standardized radiographic assessment.

Eligibility criteria

Qualifiers

1. Patiens previously enrolled in the randomized clinical trial PER-ECL-2019-05, which included 36 patients with advanced peri-implantitis.

Disqualifiers

1.Did not complete the original clinical trial protocol (PER-ECL-2019-05) or withdrew before final evaluation.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

34 Participants
are grouped into 1 trial group

Sponsors and collaborators

Ramón Pons Calabuig

Lead sponsor

Universitat Internacional de Catalunya

Sponsor institution